Navigation Links
RNA Aptamers: A New Paradigm in Cancer Diagnosis and Treatment, New Life Science Webinar Hosted by Xtalks
Date:10/30/2013

Toronto, Canada (PRWEB) October 30, 2013

RNA aptamers are an emerging class of molecules demonstrating significant potential in the diagnosis and treatment of human diseases. RNA aptamers are small, single-stranded RNA molecules that are functionally analogous to antibodies. However, RNA aptamers can be produced by chemical synthesis and their small size, low immunogenicity, and other attributes give them important advantages over antibodies. In addition, stable, ribonuclease-resistant RNA aptamers can be readily produced which further extends their use for both in vitro and in vivo applications.

This presentation will focus on the use of RNA aptamers for developing cancer diagnostics and treatments.

Join the panel including speakers from University of Miami, University of Arlington, TX, and University of Iowa, as they discuss techniques and methods involved in:

  •     Selecting and using RNA aptamers as therapeutic agents
  •     Targeted delivery of therapeutics such as siRNA
  •     Development of biosensors/diagnostics for early cancer detection

A Q&A with the audience will follow the main presentation.

For more information about this event or to register, visit: http://xtalks.com/rna-aptamers-in-cancer-diagnosis-and-treatment.ashx .

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Michelle Tran, Marketing Manager
+1 (416) 977-6555 ext 284
mtran(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/10/prweb11269970.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. INCOM Inc. Announces Acquisition of Paradigm Optics
2. Unique properties of graphene lead to a new paradigm for low-power telecommunications
3. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
4. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
5. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
6. Study Published in Nature Biotechnology Demonstrates Ability of Modernas Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue
7. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
8. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
9. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
10. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
11. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... 2016  In five studies being presented today during ... and Exposition in San Diego , ... the delivery of life-saving treatments to patients with a ... to carry therapies directly to the sites in the ... a substantial advantage over traditional, systemic methods. The studies ...
(Date:12/2/2016)... OAKS, Calif. , Dec. 2, 2016 Amgen ... AGN ) today announced the submission of a Marketing ... ABP 215, a biosimilar candidate to Avastin ® (bevacizumab). ... application submitted to the EMA. "The submission ... as Amgen seeks to expand our oncology portfolio," said ...
(Date:12/2/2016)... , ... December 01, 2016 , ... ... tube systems for North American hospitals, will present its chain-of-custody solution for tracking ... Exhibition in Las Vegas, Nev., Dec. 4-8, 2016. , Aerocom has a proven ...
(Date:12/2/2016)... (PRWEB) , ... December 02, ... ... (ETC), a consortium of pharmaceutical and biotechnology companies dedicated to collaboratively developing ... companies interested in supplying a vendor-supported, portable online UHPLC, with robust, probe-based ...
Breaking Biology Technology:
(Date:11/29/2016)... 29, 2016 BioDirection, a privately held medical ... the objective detection of concussion and other traumatic brain ... completed a meeting with the U.S. Food and Drug ... Pre-Submission Package. During the meeting company representatives reviewed plans ... precursor to commencement of a planned pilot trial. ...
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, a ... for public safety, investigation, corrections and monitoring, announced today ... competitor, ICSolutions, to have an independent technology judge determine ... most modern high tech/sophisticated telephone calling platform, and the ... that they do most of what we do – ...
Breaking Biology News(10 mins):